In fact, the demand for Byetta has been so strong that Amylin and its partner in crime Eli Lily (NYSE:LLY), asked doctors back in April to limit the number of patients they started on the drug because of shortage. That restriction was lifted in August and I suspect this will bode well for the upcoming earnings. Additionally, Amylin is expecting Byetta to be approved in Europe over the next couple of months. I recommend accumulating this stock ahead of the earnings - I am expecting them to have a good quarter.
AMLN 1-yr chart: